Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Calidi Biotherapeutics ( (CLDI) ) is now available.
Calidi Biotherapeutics, Inc. announced a reverse stock split at a 1-for-12 ratio, approved by stockholders on July 9, 2025, and effective on August 4, 2025. This move aims to optimize market dynamics and broaden investor appeal, although the company cannot guarantee the desired effects. The split adjusted the number of shares without affecting the company’s capitalization or the rights of stockholders, except for minor adjustments due to fractional shares.
The most recent analyst rating on (CLDI) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Calidi Biotherapeutics stock, see the CLDI Stock Forecast page.
Spark’s Take on CLDI Stock
According to Spark, TipRanks’ AI Analyst, CLDI is a Underperform.
Calidi Biotherapeutics’ overall stock score reflects significant financial and technical challenges, typical of a developing biotech company. While corporate events bring positive leadership changes and strategic advancements, the company’s lack of revenue, high leverage, and bearish technical indicators weigh heavily on its score.
To see Spark’s full report on CLDI stock, click here.
More about Calidi Biotherapeutics
Calidi Biotherapeutics, Inc. is a Delaware-based company operating in the biotherapeutics industry. The company focuses on developing innovative therapies and optimizing market dynamics to enhance investor appeal and accessibility.
Average Trading Volume: 1,455,109
Technical Sentiment Signal: Sell
Current Market Cap: $20.86M
Find detailed analytics on CLDI stock on TipRanks’ Stock Analysis page.